title: Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party.
abstract: The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.
authors.affiliation: 1] EBMT Lymphoma Working Party, Paris, France [2] BMT Department, Fundeni Clinical Institute, Fundeni Hospital, Bucharest, Romania.
authors.forename: A
authors.initials: A
authors.lastname: Tanase
authors.affiliation: 1] EBMT Lymphoma Working Party, Paris, France [2] Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.affiliation: Pathodiagnostik Berlin, Berlin, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Stein
authors.affiliation: EBMT Lymphoma Working Party, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Boumendil
authors.affiliation: EBMT Lymphoma Working Party, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Finel
authors.affiliation: Humanitas Cancer Center, Rozzano, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Castagna
authors.affiliation: Institut Paoli Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.affiliation: CHU Bordeaux, Bordeaux, France.
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.affiliation: Gazi Universitesi Tip Fakultesi, Ankara, Turkey.
authors.forename: G
authors.initials: G
authors.lastname: Sucak
authors.affiliation: 1] EBMT Lymphoma Working Party, Paris, France [2] Servei d' Hematologia, Institut Catala d'Oncologia- Hospital Duran i Reynals, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.affiliation: University College London Hospital, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Thomson
authors.affiliation: St James's Hospital, Dublin, Ireland.
authors.forename: E
authors.initials: E
authors.lastname: Vandenberghe
authors.affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
authors.forename: A
authors.initials: A
authors.lastname: Vitek
authors.affiliation: 1] EBMT Lymphoma Working Party, Paris, France [2] Department of Medicine, University of Heidelberg, Heidelberg, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Dreger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003299:Cooperative Behavior; D016208:Databases, Factual; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012042:Registries; D012189:Retrospective Studies; D013160:Splenic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome